NAD+ Baseline

Initiated in collaboration with Duke Clinical Research Institute, this clinical trial will evaluate correlations between epigenetic aging (measured using Index) and NAD+ levels in healthy adults; expected completion 2022/2023.

Next up:

Non-Alcoholic Fatty Liver (NAFL)

Completed human clinical trial to study the effects of Basis on liver fat accumulation in healthy adults with fatty liver; results will be announced in 2022 and published by 2023.

Acute Kidney Injury (AKI) Phase I

Published in BMC Nephrology, the Phase I human clinical trial, conducted in partnership with Massachusetts General Hospital, enabled the FDA approval of an Investigational New Drug application for Basis and the AKI Phase II trial.

Acute Kidney Injury (AKI) Phase II

Initiated at Mayo Clinic, the human clinical trial will evaluate the efficacy of Basis for the prevention of AKI in patients that have undergone a cardiac surgery; primary study completion date October 2023.